Ovarian carcinoma is the most lethal gynecologic malignancy. 1, 2 There are several morphological subtypes of ovarian carcinoma and serous type is the most common. The molecular tumorigenesis leading to this heterogeneous group of ovarian cancers is mostly unknown because of the lack of a universal tumor progression model. However, based on several clinicopathologic and molecular genetic studies, a dualistic model of ovarian serous carcinogenesis was recently proposed and is now gaining widespread acceptance. [2] [3] [4] It is presumed that low-grade serous carcinoma develops in a stepwise manner such as an adenoma-carcinoma sequence in which a benign serous cystadenoma develops into a usual serous borderline tumor, a noninvasive micropapillary serous carcinoma, and finally to a low-grade serous carcinoma.
RAS oncogenes play a pivotal role in tumorigenesis. RAS mutation was first reported in malignant melanoma, lung, and papillary thyroid carcinoma. [6] [7] [8] [9] In non-invasive and invasive ovarian carcinoma, mutation of KRAS and BRAF has previously been described with KRAS mutation which was mostly detected in mucinous ovarian tumor and in serous borderline tumors, but not in invasive serous carcinoma. [2] [3] [4] [10] [11] [12] [13] [14] [15] TP53 is a tumorsuppressor gene that is located on the short arm of chromosome 17 and encodes a 53-kDa nuclear protein that is involved in the regulation of cell growth. Mutation of the TP53 gene is the most common mutation in human cancers. 16 It has been suggested that p53 protein alterations due to missense mutations and loss of the p53 protein by nonsense or frameshift mutations might play important roles in clonal expansion of neoplastic cells. 17 Recently, the dualistic pathway was supported by molecular genetic differences in the frequency of KRAS, BRAF, and TP53 mutations between low-grade and high-grade serous carcinomas, with KRAS and BRAF mutations being more frequent and TP53 mutations being less common in low-grade serous carcinomas. 2, 4, 14, 18 Despite increasing acceptance of the dualistic model, relatively few studies have attempted to provide evidence that supports or refutes this carcinogenesis model. Determination of the molecular pathways involved in the development of ovarian serous carcinoma would markedly improve our understanding of its pathogenesis, thereby providing a basis for the development of new diagnostic tests and therapeutic strategies. Therefore, the aim of this study was to analyze the molecular genetic changes, including KRAS, BRAF, and TP53 mutations, in Korean patients with ovarian serous carcinoma and to evaluate the clinical outcomes in these 2 morphologically distinct ovarian serous carcinomas.
Patient population and clinical data
The surgical pathology files of the Department of Obstetrics and Gynecology, University of Ulsan, the Asan Medical Center, during the period between January 1996 and August 2003 were searched for all cases of ovarian tumors diagnosed as serous carcinomas. Of 164 cases identified, 104 cases with available slides were enrolled for evaluation. The medical records, including clinical outcomes, were reviewed. All patients underwent surgery, and operative reports were reviewed. The following information was taken from the medical records: age, serum CA-125 level at the time of diagnosis, International Federation of Gynecology and Obstetrics (FIGO) stage, dimension of residual tumor, clinical status at completion of primary chemotherapy, date of last contact or death, and date of disease progression. The debulking operation was defined as optimal if the largest tumor mass remaining was less than 2 cm in diameter.
Histological evaluation
All slides were reviewed by a gynecologic pathologist. Cases were classified according to the universal grading system. 19, 20 Architectural grade, nuclear grade, and mitotic count were scored each. Final grading was made as follows; total scores of 3-5 for Grade 1, total scores of 6-7 for Grade 2, and total scores of 8-9 for Grade 3. In this study, Grade 2 carcinomas were excluded in order to minimize difference of reproducibility. A total of 100 patients with low-grade (Grade 1) or high-grade (Grade 3) carcinoma were compared and analyzed.
Tissue section and tumor DNA samples Paraffin-embedded tissues from 20 low-grade serous carcinomas and 17 high-grade serous carcinomas were used for molecular genetic analysis. Of low-grade serous carcinoma specimens, three were stage I, one was stage II, 13 were stage III, and three were stage IV. In high-grade serous carcinoma group, one with stage I, 1 with stage II, 14 with stage III and 1 with stage IV were included. The histological region of interest was identified on a hematoxylin-eosin-stained section, which was marked and cut into 3-6 serial sections. DNA was purified from each section and the KRAS, BRAF, and TP53 genes were assessed for mutations using digital PCR-based techniques.
Amplification of KRAS, BRAF and T53 genes
Fifty nanograms of DNA were amplified in a 20 µL reaction solution containing 2 µL of 10X buffer (Roche, Mannheim, Germany), 1.7-2.5 mmol/L MgCl2, 0.3 µM each of primer pair (primer sequences) ( Table 1) , 250 µM deoxynucleotide triphosphate, and 2.5 units of DNA polymerase (Roche). The Polymerase Chain Reaction (PCR) program for KRAS amplification involved a single denaturation step at 95˚C for 5 minutes, followed by 35 cycles of 30 seconds at 95˚C (denaturation), 30 seconds at 55˚C (annealing), and 40 seconds at 72˚C (extension), followed by 10 minutes at 72˚C Amplifications of the BRAF and TP53 genes involved a 5-minute initial denaturation step at 94˚C, followed by 30 cycles of 1 minute at 94˚C, 1 minute at 59˚C, and 1 minute at 72˚C, and a 10-minute final extension step at 72˚C. PCR products were then 2% gelpurified with a QIAgen gel extraction kit (Qiagen).
MATERIALS AND METHODS
Direct sequencing DNA templates were processed for the DNA sequencing reaction using the ABI-PRISM BigDye Terminator version 3.1 (Applied Biosystems, Foster, CA, USA) with both forward and reverse sequence-specific primers. (Fig. 1) .
RESULTS

KRAS
We found that 6 (30%) low-grade serous carcinomas contained activating KRAS mutations at codon 12 (mutations of GGT to GAT), but these mutations were not found in high-grade serous carcinomas (Table 3 , Fig. 2 ).
BRAF BRAF mutations were not found in any of the high-grade serous carcinomas, whereas the BRAF mutation was identified only in low-grade serous carcinomas. Two cases (10%) of lowgrade carcinoma contained a mutation in exon 15, and codon 600 was affected (V600E) (Fig. 2) . KRAS and BRAF mutations were mutually exclusive.
TP53
TP53 mutations were found in 4 of the 20 (20.0%) cases of low-grade serous carcinoma. Of these four mutations, three were missense mutations and 1 was a mutation that affected the splicing site. By contrast, mutations were found in 12 of the 17 (70.6%) cases of high-grade serous carcinoma, 6 of which were missense mutations, 2 were nonsense mutations, and 4 were deletion mutations (Fig. 3) . The frequency of TP53 mutations was significantly higher in high-grade than in low-grade serous carcinomas (p = 0.009).
The importance of stage and residual disease status as prognostic factors in ovarian serous carcinoma is universally accepted, 21 but the significance of histologic grade has been questioned due to the lack of a uniform grading system and poor reproducibility. Universal grading system has been used with good reproducibility, and its prognostic use in cases of ovarian epithelial tumors has been statistically supported. 19, 22 In the present study, the patients with grade 1 and grade 3 except grade 2 were selected to evaluate the clinical outcomes and prognostic role of these 2, morphologically distinct, ovarian 
DISCUSSION
serous carcinomas. We found that histologic grade did not have a prognostic role in each FIGO stage, nevertheless, our findings suggested clinical differences between low-grade serous carcinoma and high-grade serous carcinoma. In our study population, the age range for patients with low-grade serous carcinoma was rather large, but the median age of 44 years was much younger than that of patients with high-grade serous carcinoma (54 years) and there were more premenopausal women in the low-grade carcinoma group. These findings were similar to a previous report from M. D. Anderson that the median age at diagnosis was 43 years 23 and the median age of women with epithelial ovarian cancer (approximately 90% of which are high grade carcinoma) was 59-60 years. 24, 25 In addition, low-grade serous tumors were diagnosed in more early stage (stage I and II). There were no statistically significant differences in prognosis according to FIGO stage between the two groups, but the low-grade carcinoma group showed a trend for improved progression-free survival compared with the high-grade carcinoma group of early stage. Our results add to previous studies that low-grade serous carcinoma is slow-glowing indolent neoplasm, but shows different feature from previous study that low-grade carcinoma is characterized by prolonged survival in advanced stage. 23, 26 However, these data indicate the possibility that low-grade and high-grade serous carcinomas are two different tumor types, each with their own pathogenesis rather than different grades of the same neoplasm.
In a previous mutation study, KRAS mutations were observed in approximately 50% of serous tumors with low malignant potential and low-grade serous carcinomas, however, no KRAS mutations were found in high-grade serous carcinomas. 
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either BRAF or KRAS mutations in 68% of low-grade serous carcinomas and in 61% of serous tumors of low malignant potential, but in none of the high-grade serous carcinomas. 4 Furthermore, none of the low-grade tumors contained mutations in both KRAS and BRAF, indicating that these mutations are mutually exclusive. It has also been suggested that analysis of the other components of this pathway will reveal other mutations in the 40% of cases without KRAS and BRAF mutation. As alternate pathways, TP53 and PTEN/PIK3CA mutations were suggested. 1 The main role of PTEN is a phosphatase activity, antagonizing the PI3 kinase/AKT pathway; that is, by keeping ART inactive and protecting p53 from degradation. 27 In the present study, KRAS mutations were found in 30%, BRAF mutations were found in 10%, and KRAS or BRAF mutations were found in 40% of low-grade serous carcinomas, whereas no BRAF or KRAS mutations were found in high-grade serous carcinoma. However, our study reported lower frequencies of KRAS or BRAF mutations than previous studies, and we suggest that the number of carcinomas due to mutation of another pathway-activating factor might be greater in Korean individuals.
Mutational alteration of the TP53 gene was reported in 30-80% of cases of epithelial ovarian cancer, 16, 28, 29 but few studies directly compared the expression of TP53 in low-grade and high-grade serous carcinomas. A recent study found functional TP53 mutations in only one of 12 (8.3%) low-grade serous carcinomas and in 30 of 59 (50.8%) high-grade serous carcinomas. 13 The present study found TP53 mutations in 20.0% of low-grade serous carcinomas and 70.6% of highgrade serous carcinomas, which is significantly greater than the incidence of low-grade serous carcinoma, but similar to the incidence of high-grade serous carcinoma previously reported. In this study, we found slightly increased incidences of TP53 mutation in both groups compared with the previous study. However, based on the finding that there were TP53 mutations without combined KRAS or BRAF mutations in 20.0% of lowgrade serous carcinomas, the possibility that they are involved in progression of low-grade to high-grade serous carcinomas cannot be excluded. In addition, the possibility that other pathways are involved should also be considered. Shih et al. 11 described a micropapillary pattern simulating low-grade serous carcinoma which have had TP53 mutations and lacked mutations of KRAS or BRAF. These tumors displaying a micropapillary architecture developed from a subset of lowgrade serous carcinomas that lacked mutation of KRAS and BRAF and subsequently acquired a TP mutation, which in turn might increase the level of nuclear atypia. 30 We suggest that the above described suggestions might be able to explain higher frequency of TP53 mutation in Korean women.
In conclusion, our findings support those of earlier clinical studies that low-grade serous carcinomas seem to have age distribution and mutational pattern distinct from high-grade serous carcinomas. However, there were no significant differences in stage distribution and survival, especially in advanced stage, between 2 groups, we therefore suggest that more studies are needed to segregate these patients into distinct disease entities.
